SCHEMBL3524871

SCHEMBL3524871

FC(F)(F)c1nc2ccccc2n1C1C[C@H]2CC[C@@H](C1)N2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR5 P51681 1/20 0.45
FPR2 P25090 1/20 0.43
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
HPGD P15428 1/20 0.42
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
MAPK1 P28482 1/20 0.39
PIK3CB P42338 1/20 0.39
MAPT P10636 1/20 0.39
CYP3A4 P08684 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
POLB P06746 1/20 0.37
LMNA P02545 1/20 0.36
TSHR P16473 1/20 0.36
OPRM1 P35372 1/20 0.36
OPRD1 P41143 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13543531 1.00 CCR5 (0.45) CCR5FPR2KDM4EALDH1A1HPGD
SCHEMBL31389529 0.82 CCR5 (0.47) CCR5FPR2KDM4EALDH1A1HPGD
SCHEMBL988877 0.79 CCR5 (0.49) CCR5FPR2CYP2D6MAPK1MEN1
SCHEMBL3863093 0.79 CCR5 (0.49) CCR5FPR2CYP2D6MAPK1MEN1
SCHEMBL3526098 0.79 SMN1; SMN2 (0.44) OPRM1OPRD1OPRK1OPRL1
SCHEMBL13543533 0.79 SMN1; SMN2 (0.44) OPRM1OPRD1OPRK1OPRL1
SCHEMBL13720260 0.79 CCR5 (0.49) CCR5FPR2CYP2D6MAPK1MEN1
SCHEMBL4028493 0.79 CCR5 (0.49) CCR5FPR2CYP2D6MAPK1MEN1
SCHEMBL3529180 0.79 NOS2 (0.44) CCR5CYP1A2CYP2D6POLBOPRM1
SCHEMBL4022749 0.79 CCR5 (0.49) CCR5FPR2CYP2D6MAPK1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7645771-B2 CCR5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORP. (US) 2010-01-12 US disclosed
US-20060229336-A1 Ccr5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORPORATION 2006-10-12 US disclosed
EP-1569646-A2 PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2005-09-07 EP disclosed
WO-2004054974-A2 PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2004-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229336-A1 Ccr5 antagonists as therapeutic agents CCR5, CCR1, CXCR3 CCR5 1/4885FPR2 49/4885KDM4E 4644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.